Center for Radiopharmaceutical Sciences (CRS)The Center for Radiopharmaceutical Sciences, headed by Prof. Dr. Roger Schibli, is a joint endeavor between the Paul Scherrer Institute, the ETH Zurich and the University Hospital Zurich, and is working towards clinical application of radiopharmaceuticals based on an interdisciplinary approach involving radiochemistry, radiopharmaceutical chemistry, biochemistry, molecular biology, pharmacy and pharmacology.
The main focus of our research at PSI is the development of novel radioactive drugs for non-invasive diagnosis and therapy of metastatic cancerous lesions. The powerful high energy cyclotron and neutron source SINQ at PSI enable the production and development of novel radionuclides to this end. We are doing this in close cooperation with the Laboratory of Radiochemistry at PSI, headed by Dr. Robert Eichler.
At our laboratories at the ETH and the USZ we develop novel 11C and 18F PET-tracers for the tumor detection and the visualization of diseases of the brain and the heart.
CRS offer the entire spectrum of radiopharmaceutical sciences which includes basic radiolabeling chemistry, lead-optimization, in vitro and in vivo assessment, pre-clinical nuclear imaging (PET and SPECT) and radionuclide therapy as well as translation of new and novel radiotracers for clinical studies (in collaboration with academic and industrial partners).